https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Sustained Benefits of Long-Term VMAT2 Inhibitor Therapy in Tardive Dyskinesia

Sustained Benefits of Long-Term VMAT2 Inhibitor Therapy in Tardive Dyskinesia

Panelists discuss how open-label extension studies of VMAT2 inhibitors demonstrate sustained efficacy, tolerability, and patient retention in long-term treatment of tardive dyskinesia—including in older adults—highlighting their potential to improve quality of life despite manageable adverse effects.

administrator

Related Articles